Concepedia

Roger M. Lyons

RM

Statistics

Publications

85

Citations

10.1K

H-Index

42

Active since

1971

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Amgen (United States)

Cornell University

Texas Oncology

Emory University

Roger M. Lyons is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacology, and hematology.

ORCID

Publications per year

1971–2024

85

Publications

85

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

, , +12

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

David J. Kuter, James B. Bussel, Roger M. Lyons et al. · The Lancet · 2008 · 862 citations

, , +6

AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP

James B. Bussel, David J. Kuter, James N. George et al. · New England Journal of Medicine · 2006 · 530 citations · Full text

, , +7

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

James B. Bussel, David J. Kuter, Vinod Pullarkat et al. · Blood · 2008 · 433 citations · Full text

, , +6

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Journal of Hematology & Oncology · 2017 · 427 citations · Full text

, , +10

1–5 of 85